LQDA: Liquidia Technologies Kompaniya qiymatining sof foydaga nisbati

Liquidia Corp (LQDA) korporativ emblemasi va logotipi

Liquidia Corporation (LQDA) uchun narx-foyda koeffitsiyenti tendentsiyasi o'pka gipertenziyasini davolash uchun Yutrepia dori vositasining tijoratlashtirilishiga oid kutishlarni aks ettiradi. -54.30 qiymati ushbu parametrning miqdorini ifodalaydi. Biznesni rivojlantirish AQSh dori yetkazib berish markazlariga tayanadi. Aktivlarning barqarorligi inhalatsiya usullari uchun patent himoyasi bilan ta'minlanadi, bu esa dorini yuborishning qulayligi tufayli foyda o'sishi uchun sezilarli imkoniyatlar yaratadi.

LQDA Liquidia Inc.: Narx-foyda koeffitsiyenti 04.07.2022 - 15.11.2026 oraligʻida

Liquidia Corp (LQDA) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning har tomonlama tahlili:Liquidia Corp - LQDA
Liquidia yetakchi tovari

P/E koeffitsiyenti sof foydaning bir birligining bozor qiymatini aks ettiradi, bu esa investorga aktivning haddan tashqari qimmat baholanganlik darajasini yoki uning potentsial past baholanganligini aniqlash imkonini beradi. Liquidia Corporation (LQDA) kompaniyasining taxminiy P/E koeffitsiyentini tahlil qilish joriy bozor kutuvlarini mualliflik huquqiga ega dori vositalarining uzoq muddatli sertifikatlashtirish muddatlari bilan muvofiqlashtirishga yordam beradi, bunda klinik sinovlarning muvaffaqiyatsizligi xavfi biznesning adolatli baholash koeffitsiyentiga bevosita ta'sir qiladi.

Raqobatdosh kompaniyalar tahlili

HLN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Jyong Biotech Limited MENS|Ligand (LGND) - Kapitalizatsiyaning foydaga nisbati|AMRX: Narx-foyda koeffitsiyenti|Perrigo - Bozor narxining sof foydaga nisbati|ALVO: P/E multiplikatori|Galapagos Genomics - Kompaniya qiymatining sof foydaga nisbati|ANIP (ANI Pharmaceuticals Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati mannkindcorp.com MNKD|Narxning foydaga nisbati Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SPRY (ARS Pharmaceuticals Inc)|Bozor narxining sof foydaga nisbati TBPH (Theravance)|AQST - Narxning foydaga nisbati|scPharmaceuticals (SCPH) - Narx-foyda koeffitsiyenti|TECX: P/E multiplikatori|Narx-foyda multiplikatori TNXP|Narxning foydaga nisbati China SXT Pharmaceuticals, Inc.|EPRX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori BHST|EXOZ - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ORMP (oramed.com)|P/E multiplikatori enterabio.com ENTX|HYFT - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati ABVC BioPharma, Inc ABVC|CPIX: P/E multiplikatori|Quantum BioPharma Ltd - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti FGEN|Telomir Pharmaceuticals, Inc. - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori RANI|SNYR (Synergy CHC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Rallybio RLYB|Lexaria Bioscience (LEXX) - Kapitalizatsiyaning foydaga nisbati|PULM - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pheton Holdings PTHL|APM (Aptorum) - Narx-foyda koeffitsiyenti|Lyra Therapeutics, Inc. (LYRA) - P/E multiplikatori|IBO (impactbiomedinc.com) - P/E multiplikatori|TNFA (TNF Pharmaceuticals) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati cbdmd.com (YCBD)|Biznesning o‘zini qoplash muddati PainReform Ltd|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Kapitalizatsiyaning foydaga nisbati|OPTN - Narxning foydaga nisbati|Pieris Pharmaceuticals - Bozor narxining sof foydaga nisbati|PROC (Procaps Group) - Narx-foyda koeffitsiyenti|PTPI - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qilian International Holding Group Limited|SLRN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TFFP (TFF Pharma)